Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference  by Jha, Vivekanand et al.
meet ing repor t www.k idney - i n t e rna t i ona l . o rgOPENimplementation strategies in low- and
Understanding kidney care needs and
middle-income countries: conclusions from a
“Kidney Disease: Improving Global Outcomes”
(KDIGO) Controversies Conference
Vivekanand Jha1,2, Mustafa Arici3, Allan J. Collins4,5, Guillermo Garcia-Garcia6, Brenda R. Hemmelgarn7,
Tazeen H. Jafar8,9,10, Roberto Pecoits-Filho11, Laura Sola12, Charles R. Swanepoel13,
Irma Tchokhonelidze14, Angela Yee Moon Wang15, Bertram L. Kasiske16, David C. Wheeler17 and
Goce Spasovski18; for Conference Participants19
1George Institute for Global Health, New Delhi, India; 2University of Oxford, Oxford, UK; 3Department of Nephrology, Hacettepe University
Faculty of Medicine, Ankara, Turkey; 4Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis,
Minnesota, USA; 5Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA; 6Nephrology Service, Hospital Civil de
Guadalajara, University of Guadalajara Health Sciences Centre, Hospital 278, Guadalajara, Jalisco, Mexico; 7Department of Community
Health Sciences, Libin Cardiovascular Institute, Institute of Public Health, and Department of Medicine, University of Calgary, Calgary,
Alberta, Canada; 8Program in Health Services & Systems Research, Duke-NUS Graduate Medical School, Singapore; 9Department of
Community Health Science, Aga Khan University, Karachi, Pakistan; 10Section of Nephrology, Department of Medicine, Aga Khan
University, Karachi, Pakistan; 11School of Medicine, Pontiﬁcia Universidade Católica do Paraná, Curitiba, Brazil; 12Comité de Salud Renal
del Ministerio de Salud Publica de Uruguay, Montevideo, Uruguay; 13Division of Nephrology and Hypertension, Groote Schuur Hospital
and University of Cape Town, South Africa; 14Nephrology Development Clinical Center, Tbilisi State Medical University, Tbilisi, Georgia;
15Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong; 16Division of Nephrology, Hennepin County
Medical Center, Minneapolis, Minnesota, USA; 17University College London, London, UK; and 18University of Skopje, Medical Faculty,
University Department of Nephrology, Skopje, MacedoniaEvidence-based cinical practice guidelines improve delivery
of uniform care to patients with and at risk of developing
kidney disease, thereby reducing disease burden and
improving outcomes. These guidelines are not well-
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middle-income countries (LMICs). The KDIGO Controversies
Conference on Implementation Strategies in LMIC reviewed
the current state of knowledge in order to deﬁne a road
map to improve the implementation of guideline-based
kidney care in LMICs. An international group of
multidisciplinary experts in nephrology, epidemiology,
health economics, implementation science, health systems,
policy, and research identiﬁed key issues related to
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existing guidelines in different geographical regions.
Kidney International (2016) 90, 1164–1174; http://dx.doi.org/10.1016/
j.kint.2016.09.009
KEYWORDS: acute kidney injury; advocacy; chronic kidney disease; clinical
practice guidelines; implementation; low and middle income countries
Copyright ª 2016, International Society of Nephrology. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
K idney diseases (KDs), both acute and chronic, arerecognized as major public health issues worldwide.More than half of patients with advanced chronic
kidney disease (CKD) do not receive any treatment, especially
in the low and low middle income countries (LMICs).1
Similarly, acute kidney injury (AKI) contributes to about
1.7 million preventable deaths every year worldwide.2
Implementation of existing knowledge can substantially
reduce KD burden and improve outcomes. Kidney Disease:
Improving Global Outcomes (KDIGO) has been at the fore-
front in developing evidence-based best practice guidelines to
optimize the management of KD patients. Using rigorous
methodology that represents the best global science, KDIGO
has produced 9 guidelines and held 25 conferences onKidney International (2016) 90, 1164–1174
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Figure 1 | Interaction of traditional and nontraditional risk
factors in the epidemiology of CKD.
V Jha et al.: Kidney care in low- and middle-income countries mee t ing repor timportant issues in KDs and their treatment. The KDIGO
guidelines have been adapted and/or adopted by several pro-
fessional organizations, and disseminated through publica-
tions, seminars, webinars, symposia, and in digital format.
Thus, KDIGO aims at providing the highest level of guideline-
based care that can be adapted for local needs and models of
care, including in the presence of resource limitations.
Over time, it has become apparent that these guidelines are
not well-integrated into routine care in the LMICs. To achieve
an international, multidisciplinary, transparent, and unbiased
analysis, KDIGO brought together experts from around the
world to a Controversies Conference in Bangkok, Thailand, in
June 2015 to identify means to overcome the barriers to
improved nephrology care in resource-constrained settings.
CONFERENCE METHODS AND PARTICIPANTS
Drs. Vivekanand Jha (George Institute for Global Health, New
Delhi, India) and Goce Spasovski (University of Skopje, Skopje,
Macedonia) co-chaired this conference. Theobjectiveswere to: (i)
develop and deliver arguments for policies to implement
guideline-based care; (ii) summarize the current state of knowl-
edge on health systems andKDburden in LMICs; (iii) discuss the
technological and manpower restructuring innovations needed
to improve guideline-based delivery of kidney care; and (iv) assess
requirements to develop resource-sensitive guidelines by under-
standing thebarriers and facilitators of guideline implementation.
The overall aim of this conference was to propose approaches to
help facilitate implementation of evidence-based clinical practice
guidelines for the care of patients with KD in LMICs. To this end,
consensus was achieved on the recommended action plans based
onplenary presentations anddiscussions at themeeting, narrative
literature reviews, and deliberations on a series of questions
deﬁned in advance of the meeting.
The conference included experts in nephrology, epidemi-
ology, health economics, implementation science, health
systems, policy, and research. Participants worked in break-
out groups to review strategies and develop recommenda-
tions for advancing models of care and research in the LMIC
setting. Conference details can be found at http://kdigo.org/
home/conferences/implementation-strategies/.
SETTING THE STAGE
Demographic and disease transitions in LMICshave produced a
growing burden of KD. Persisting public health issues such as
inadequate sanitation, lack of safe drinking water, suboptimal
infection control and reproductive health, and environmental
hazards continue to generate a large and preventable burden of
AKI and CKD.3 Increasing urbanization, lifestyle and dietary
changes have brought on an escalating burden of non-
communicable diseases (NCDs), which increases the risk of
CKD (Figure 1).4 Malnutrition affects serum creatinine, inter-
fering with its role as a diagnostic marker. Maternal malnutri-
tion may result in low–birth weight neonates, which imposes a
lifetime risk of developing diabetes, hypertension, and CKD.5
Health care systems in LMICs often exhibit a lack of
evidence-based policy, mismatch between disease burden andKidney International (2016) 90, 1164–1174care provisions, shortage and maldistribution of care pro-
viders, absence of organized primary care, fragmentation and
disparities in access and quality, and reliance on unproven
therapies. The high cost of treatment, combined with lack of
reliable social security, results in out-of-pocket payments,
pushing families into poverty.
DEVELOPING AND DELIVERING ARGUMENTS FOR IMPROVED
HEALTH POLICIES TO IMPLEMENT GUIDELINE-BASED CARE
Most LMICs have prioritized spending the limited funds
available for health care to combat malnutrition, prevent in-
fectious diseases, and improve reproductive health, as
articulated in the Millennium Development Goals established
by the United Nations (UN) (https://www.un.org/mill
enniumgoals/). Most countries made substantial prog-
ress, and earlier this year, the UN announced a new Sus-
tainable Development agenda. In setting up the Sustainable
Development Goal (SDG) targets, the UN panel took into
account the rising global burden of premature deaths and
disabilities due to NCDs. The new health-related SDG in-
cludes reducing by one-third premature mortality due to
NCDs through prevention and treatment (http://www.un.org/
sustainabledevelopment/health/). The SDG 3.8 calls for
achievement of universal health coverage, including ﬁnancial
risk protection; access to quality essential health care services;
and access to safe, effective, quality, and affordable essential
medicines for all, making prevention/treatment of AKI and
CKD progression a complementary goal rather than a
competing one, while combating malnutrition and infections
for overall health care improvement in LMICs.
NCDs are currently the driving force of CKD throughout the
world, with regional nephropathies such as infection-related
glomerulonephritides and Mesoamerican, Balkan, and
Chinese herbal nephropathies being important causes of CKD1165
Table 1 | Possible targets for the advocacy initiative
 Recognize preventable deaths due to AKI in LMICs as a human rights
issue
 Recognize CKD as an important cause of death and disability by na-
tional health authorities
 Include screening and management for AKI and CKD in existing or
planned NCD and CD programs
 Reduce cardiovascular morbidity and mortality in those with CKD
 Retard progression of CKD and the need of RRT
 Increase government funding for CKD detection and prevention
 Increase access to RRT in an equitable and just manner
 Increase rates of organ donation and transplantation
 Establish a national ESRD registry
AKI, acute kidney injury; CD, communicable diseases; CKD, chronic kidney disease;
ESRD, end-stage renal disease; LMICs, low- and middle-income countries; NCD, non-
communicable diseases; RRT, renal replacement therapy.
Modiﬁed from Tonelli M et al.11
meet ing repor t V Jha et al.: Kidney care in low- and middle-income countriesin certain LMICs.6 Lack of awareness, failure to recognize early
signs, and improper management contribute to CKD burden.7
Between 1990 and 2013, the global years of life lost and years
lived with disability due to CKD rose by 90%8 and 49.5%,9
respectively. A recent analysis revealed a higher age-
standardized global prevalence of CKD in adults in LMICs
(10.6% in men and 12.5% in women) than in high-income
countries (8.6% in men and 9.6% in women).10 The total
number of adults with CKD worldwide was estimated to be
497.5 million, with 387.5 million in LMICs (Supplemental
Figure S1).10
Despite its importance, KD lacks visibility. Faced with a
rising burden of premature death and disability due to NCDs,
many countries are developing strategies for the prevention
and control of NCDs as suggested in the SDGs. Most, how-
ever, do not speciﬁcally address KD in their programs.11
Decision-makers worldwide are unaware that a large part of
the burden of adverse outcomes secondary to diabetes, hy-
pertension, and obesity is through the development of KD.12
Expressing such burden and impact in terms of health care
costs and disability (disability-adjusted life years) based on
local or national statistics is important. If local information is
not available, good-quality epidemiologic data, preferably
from matched populations, should be used. Other stake-
holders, including the target population that will beneﬁt from
intervention, governments, and potential allies should be
deﬁned. Any proposed initiative to target KD should be
harmonized with existing or planned public health initia-
tives.11 Unique forms of KD (e.g., CKD due to environmental
factors or AKI secondary to herbs, toxins, or poor obstetric
care) might require special initiatives. A health-economic
analysis of the consequences of untreated disease is helpful.
Countries that are implementing universal health care
coverage stand to realize the most savings when CKD pre-
vention programs are implemented early. Savings resulting
from prevention can be used for more important public
health needs rather than setting up expensive dialysis services.
For example, a cost-beneﬁt analysis of hypertensive patients at
risk of CKD in Peru estimated the total cost savings from
preventive interventions to be $188 million over 5 years if
dialysis is avoided.13 Prevention is the only recourse to save
lives in countries where health care systems do not cover
dialysis. The economic consequences of lost productivity,
along with the recognition that better and earlier guideline-
based care is a less expensive alternative to disease progres-
sion should be presented to policy makers as an argument for
guideline implementation.
The beneﬁts of early screening, detection, treatment, and
cost-effectiveness should be presented in the form of numbers
needed to treat and savings accrued to the health care sys-
tem.14 Studies from developed countries have demonstrated
that NCD mortality and disease incidence can be reduced by
75% and 58%, respectively, through appropriate in-
terventions.15,16 Objectives of prevention programs should be
clearly stated and prioritized, based on local resources
(Table 1).1166The importance of acute kidney Injury recognition and
prevention in LMICs
The public health narrative of KD is usually centered on CKD.
Policy makers should be made aware that preventable
community-acquired AKI poses added burden in many
LMICs. In contrast, AKI in high-income countries is largely
in hospitalized patients. A meta-analysis of 13 cohort studies
conﬁrmed that AKI is an important independent risk factor
for CKD and end-stage renal disease (ESRD), death, and
other important nonrenal outcomes.17 Repeated episodes of
AKI accelerate CKD progression.18 The 0by25 initiative of the
International Society of Nephrology has recognized reducing
preventable deaths due to AKI a “human rights” issue and
called for stakeholder engagement, public awareness, and
education of general practitioners and nonphysician health
workers on causes of AKI (e.g., infections, herbs, contami-
nated water, over-the-counter medicines, and obstetric care)
and the importance of its prevention. The 0by25 group found
that about 20% of all patients with AKI in LMICs did not
receive dialysis despite indications, largely due to absence of
resources and inability to afford cost of therapy.3 According to
Olowu et al.,19 about 80% of undialyzed patients with AKI in
sub-Saharan Africa die. The next set of studies by the 0by25
group will investigate whether AKI can be prevented by
providing guideline-based care to these patients (http://www.
0by25.org).
Table 2 describes the information that can help policy
makers understand the need to develop a KD-speciﬁc health
program.
Developing public policy for kidney disease
The public policy cycle is a 3-step process: formulation,
implementation, and monitoring and evaluation.20,21
Formulation begins with estimation of disease burden, anal-
ysis of public policy alternatives, and evaluation of cost-
beneﬁt leading to an action plan (Figure 2).11
Clearly deﬁned objectives, a guideline-based action plan,
attention to potential administrative conﬂicts, leveraging
available resources, and positive engagement of all parties are
key to successful implementation. Transparent qualitative andKidney International (2016) 90, 1164–1174
Table 2 | What data do policy makers need?
 What are the data on intensity of AKI and CKD burden and intersection
with other diseases/risk factors?
 What is the impact of kidney disease on population health and eco-
nomics (in terms of DALYs and cost of care)?
 What is the cost-effectiveness of interventions at different stages of
CKD?
 What target populations might beneﬁt from kidney disease in-
terventions (e.g., age, groups at increased risk, geographic location, or
occupations)?
 Are there local factors that exacerbate or mitigate disease risk or
implementation strategies?
 Who are the stakeholders and allies?
 Are there local evidence-based best practice management guidelines,
or can global guidelines be adapted to suit local needs?
 What innovations can improve the delivery of care for kidney disease in
an affordable and scalable manner in the context of local health
system?
 How can we evaluate effectiveness of health care intervention (i.e.,
components, process and outcome)?
 Is there a need to set up kidney disease registries?
 What is the research agenda for improving locally appropriate
implementation?
 What are the metrics for measuring successful implementation and
progress of kidney disease prevention efforts?
AKI, acute kidney injury; CKD, chronic kidney disease; DALYs, disability-adjusted life
years.
V Jha et al.: Kidney care in low- and middle-income countries mee t ing repor tquantitative indicators help measure short- and long-term
outcomes.
The role of KDIGO, national societies and other global or
regional health organizations. Local adaptation starts with
the identiﬁcation of stakeholders interested in providing
guideline-based care, such as professional societies, govern-
ments, insurance providers, or other interested groups. The
availability of local champions fosters implementation.22,23
Engagement of national or regional nephrology societies
with global organizations can play a signiﬁcant advocacy role.
The successful collaboration between Pan American Health
Organization and the Latin American Society of Nephrology
and Hypertension that started with the participation of a
Pan American Health Organization speaker at an Inter-
national Society of Nephrology / Latin American Society ofa. Define the problem 
in your region
b. Analyze public
alternatives
CKD Epidemic
Early  detectio
prevention
Rationing or li
access to RRT
Universal RRT
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Figure 2 | Steps involved in the formulation of a public health policy
Tapia-Alvarez M, Campillo-Carrete B, Cruickshank-Soria S, Morales-Sotom
at: http://www.alternativasycapacidades.org/.27 CKD, chronic kidney dise
Kidney International (2016) 90, 1164–1174Nephrology and Hypertension regional meeting in Guatemala
in 200824 resulted in the inclusion of KD within the strategies
for prevention of cardiovascular disease in the Americas and
the creation of a task force for the study of the CKD epidemic
in Central America.25,26
Patient support groups, foundations, and nongovern-
mental organizations that are already advocating for NCD
prevention and are engaged with policy makers can be
powerful allies. In addition to educational and fundraising
activities, these bodies can support advocacy to include KD in
the public health agenda by organizing and advising patients
to demand the care they need, collaborating with govern-
ments to replicate successful programs developed by
nongovernmental organizations, and facilitating imple-
mentation of public health policies.27 The steps involved in
developing an advocacy project with these organizations are
summarized in Figure 3.
Understanding barriers to implementation of guidelines in
LMICs. Implementation of guideline-based care can be
thwarted at several levels (Table 3). Resource constraints,
perceived complexity of guidelines, physician attitude, and
lack of training promote nonadherence to guidelines.28 The
National Institute for Health and Care Excellence (NICE),
UK, has suggested steps to understand, identify, and over-
come these barriers (Table 4).29 Publishing simpliﬁed
guidelines in local languages, customized educational
slide decks, ﬂow charts, algorithms, and ﬂyers can facilitate
implementation.
KIDNEY DISEASE IN THE CONTEXT OF LOCAL HEALTH
SYSTEMS AND DISEASE BURDEN
Kidney disease registries play a vital role in public policy as
public health surveillance tools. Registries provides a stan-
dardized method to collect data on disease burden, treatment,
and outcomes, and monitor evolution over time.30 In a recent
review, no renal registries were identiﬁed in many LMICs,
including India, Indonesia, the Philippines, and almost all
African countries.30,31 Establishing and maintaining a registry
requires initial investment from public funds but provides policy c. Show cost–benefit
data
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on CKD. Modiﬁed from Manual de incidencias en Politicas Publicas.
ayor G, eds. Alternativas y Capacidades AC; Mexico, DF. 2010. Available
ase; QoL, quality of life; RRT, renal replacement therapy.
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1. Identify and define 
the problem
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(formulation, implementation, 
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Figure 3 | How nongovernmental organizations can inﬂuence public health policies. Modiﬁed from Manual de incidencias en Politicas
Publicas. Available at: http://www.alternativasycapacidades.org/.27
meet ing repor t V Jha et al.: Kidney care in low- and middle-income countriesimmense value in informing development of CKD prevention
and renal replacement therapy programs.30 It also requires the
ability to identify KD using appropriate tests and availability
of dialysis and/or transplant (for ESRD registries). Countries
that are planning to develop renal replacement therapy pro-
grams should incorporate a registry as a component.Table 3 | Current barriers to kidney disease care in LMICs
 System-level barriers
B Lack of access to health insurance
B Lack of trained manpower and resources
B Lack of education around standardized, guideline-based uniformity
of care
B Lack of coordinated efforts by stakeholders in development of a
comprehensive health care response to emerging threats
B Focus on curative rather than preventive medicine
B Unregulated health care systems—no incentives for quality
improvement
B Lack of incentives for disease prevention
 Kidney disease–speciﬁc issues
B Inadequate health systems response to kidney care delivery
B Omission of kidney disease screening and management in course
curricula
B Lack of data on AKI and CKD burden and its consequences
B Inadequate understanding of risk factors for CKD development and/
or progression
B Inadequate understanding of the consequences of missed opportu-
nities for kidney disease care
B Delayed diagnosis and late presentation with advanced disease and
complications
B Fragmentation of information and communication on kidney disease
care
B Lack of locally appropriate or adapted guidelines for kidney disease
(e.g., language, complexity, implementation tools)
B Lack of standardized care tools for physicians and educational tools
for patients
AKI, acute kidney injury; CKD, chronic kidney disease; LMICs, low- and middle-
income countries.
1168Health care policies and ﬁnancing by the government are
the key determinants of access, availability, and coverage in
each country. Many countries exhibit internal heterogeneities
in health care delivery, ﬁnancing, and reimbursement pol-
icies.32,33 LMICs with limited or poor access to dialysis also
lack primary and secondary prevention programs for NCDs
such as hypertension, diabetes, and obesity, all known CKD
risk factors.
Are there common characteristics of kidney care in countries
with high kidney disease prevalence and limited resources?
In general, LMICs allocate insufﬁcient resources to health
care and have an unstructured model of care, resulting in late
presentation and referrals. Recent analysis of the Monitoring
Dialysis Outcomes (MONDO) database including data of
84,796 hemodialysis patients from 27 countries demonstrated
a signiﬁcant association between socio-economic factors,
dialysis variables, and health quality indicators.34 Low
resource allocation bears close correlation with the prevalence
of ESRD (Supplemental Figure S2).1 Late referral adversely
impacts morbidity and mortality,1 leading to urgent start
dialysis and high prevalence of temporary vascular access
usage. The renal replacement therapy choice is also affected
by the availability and cost of treatment, rather than by pa-
tient preference and clinical outcomes.35
LMICs are plagued by shortage of health care professionals
including kidney specialists, leading to nonstandard delivery
of care and poor outcomes. Kidney care, including that for
advanced CKD, is frequently provided by non-nephrologists
in LMICs.36,37 A cultural component of denial adds to sub-
optimal management and loss to follow-up. By way of
example, irregular hemodialysis frequency and nonstandard
reuse of dialyzers,36,37 variable access to drugs, and poorlyKidney International (2016) 90, 1164–1174
Table 4 | Understanding, identifying and overcoming barriers to guideline implementation
Understanding the barriers to
change Identifying the barriers to change Overcoming the barriers to change
 Awareness and knowledge
 Motivation
 Practicalities
 Acceptance and beliefs
 Skills
 The external environment
 Talk to key individuals
 Observe clinical practice in action
 Use a questionnaire
 Brainstorm
 Run a focus group
 Educational materialsa
 Educational meetings, interactive workshops
 Educational outreach visitsb
 Opinion leaders
 Clinical audit and feedbackc
 Reminder systemsd
 Patient-mediated strategies (e.g., mass
media campaigns)
aFormats and layout can affect the inﬂuence of materials in changing behavior. They are low cost but need follow up.
bAttention to the visitor, frequency, tailor to barriers.
cClinically rich data and buy-in needed.
dEspecially at decision-making points, more for in-training staff.
V Jha et al.: Kidney care in low- and middle-income countries mee t ing repor tregulated use of generics and biosimilars are frequent in
LMICs.
If universal ESRD therapy is not available in a country, what
type of care should be available to patients and the
community?
Lack of ﬁnancial resources forces patients in many LMICs to
either reduce dialysis frequency, withdraw from dialysis, or
use alternative treatments that are untested or of dubious
value. Supportive or palliative care for patients with advanced
CKD is nonexistent in LMICs. A recent KDIGO Contro-
versies Conference addressed the issue of supportive care in
CKD.38 This is best achieved through a multidisciplinary team
including nephrologists, nurses, psychosocial workers/coun-
selors, dieticians, allied health professionals, and community
leaders, many of whom may not be available in LMICs.
Research is needed on the modality and impact of supportive
care provision in LMICs on patients who cannot access
dialysis due to ﬁnancial reasons.38
Even when dialysis is available, policies for its delivery can
be arbitrary and not clearly stated, as provision is driven by
market forces. Since dialysis cannot be provided to all in-
dividuals, guidelines based on a transparent decision making,
taking into account the individual patient’s circumstances,
should be developed to optimize use of this limited resource.
Countries must set their own priorities and establish trans-
parent protocols. For example, in South African state hospi-
tals, dialysis is only offered to those who consent to receiving
a transplant when offered.39 In Thailand, an ESRD patient
can be treated for free by peritoneal dialysis, whereas those
who decline the offer and choose hemodialysis will not get
any ﬁnancial support.40
INNOVATIONS IN HEALTH CARE DELIVERY: MANPOWER
RESTRUCTURING AND USE OF TECHNOLOGY
Manpower and technology have an important impact on the
ability to implement guideline-based kidney care. Although
care by nephrologists generally results in better outcomes,41,42
shortage of nephrologists makes this impractical in LMICs.43
Because interventions to reduce KD burden are likely to be
implemented at primary care settings, it is logical to involve
general physicians and nurses.44 Non-physician health careKidney International (2016) 90, 1164–1174workers (NPHWs) have been trained successfully in deliv-
ering interventions for communicable diseases and repro-
ductive health.45 Both physician and non-physician primary
care providers should be trained in the entire spectrum of
guideline-driven prevention, detection, and management of
KD.46
Increase manpower: train more nephrologists and task shift
other providers in kidney care
Increasing the number of nephrologists through expanded,
supported, and strengthened nephrology training programs is
an important goal. This may require international coopera-
tion facilitated by global nephrology organizations. The
increased training can be counteracted by a continuing brain
drain from LMICs to high-income countries.47
Training NPHWs in early diagnosis and referral and
community management for kidney care can reduce
manpower requirements and improve outcomes. For optimal
results, such a system should be developed in the overall
context of management of chronic diseases, such as diabetes,
hypertension, and cardiovascular disease.48
Standardized algorithms/pathways should be based on
evidence-based guidelines after appropriate adaptation for
CKD prevention and management with clear decision points,
checklists, and levels of referral according to the local health
care infrastructure.42 The algorithms should include man-
agement action plans in a user-friendly format for the local
providers (including diabetologists and cardiologists).49
This effort should be complemented by development of a
master curriculum with a toolkit for local adaptation. A
trainer’s guide with instructions on standardized training,
competency, and skills assessment with requirements for
certiﬁcation and mandatory recertiﬁcation will be helpful.
Institution of quality parameters and performance incentives
have been shown to work in improving outcomes. The quality
and structure of incentives, however, may be different for
public providers and private practitioners. Education of pa-
tients and practitioners has been shown to reduce the risk of
decline in kidney function and/or death.50,51
Although dialysis ideally should be prescribed by ne-
phrologists, training primary care physicians and nurse
practitioners to work in dialysis units under nephrologist1169
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Figure 4 | Pathway to guideline implementation.
meet ing repor t V Jha et al.: Kidney care in low- and middle-income countriessupervision is advisable to meet the rising workload demands
of dialysis in LMICs.1 Appropriate utilization of such
personnel will require development of standard operating
procedures and continuous quality monitoring.
Innovation for CKD screening, awareness, and management
Population-wide screening for undiagnosed diabetes and high
blood pressure has been advocated by most professional so-
cieties and is increasingly being integrated into NCD man-
agement policies throughout the world. Large universal CKD
screening programs have taken place in the Netherlands, the
United States, Japan, and China.52,53 This strategy is of
particular importance in LMICs, where approximately half of
people affected with these conditions are undiagnosed.54
Current recommendations suggest limiting screening for
CKD to those with known risk factors such as hypertension,
diabetes, older age, family history of kidney disease, and
certain ethnicities.55 Use of point-of-care tests is important to
improve uptake, as it can provide real-time feedback to the
participants on the measured parameters.
The conference participants recognized the limitations of
current CKD screening recommendations in geographic areas
where abnormally high prevalence of CKD of nontraditional
etiology is reported.56 The scope of screening might need to be
expanded to other populations, such as to those with exposure
to novel risk factors. Geographically targeted screening of
unique at–risk populations, such as Canadian First Nations
people, has yielded increased rates of CKD detection over
nontargeted universal screening.57 Appropriately designed
studies are needed to deﬁne the magnitude of disease and risk
factors in different geographies. Practical point-of-care systems1170for glomerular ﬁltration rate estimation will need to be devel-
oped and validated because most of these patients do not
exhibit proteinuria.58 More data are required on the cost
effectiveness of screening followed by interventions (e.g., hy-
dration through “water breaks” and shade for those who work
outdoors in hot and humid ambient conditions).58–60
Clinical decision support systems can boost the ability of
NPHWs and primary care physicians to deliver uniform high-
quality, guideline-based care in the community. The efﬁciency
of this approach can be improved by using information
technology through mobile applications that can provide
decision support and management plans in real time, inte-
grated tracking and monitoring, reminder and recall service
via voice or text messaging, drug inventory management and
education materials. These tools have been shown to increase
long-term adherence to treatment and thereby delay devel-
opment and/or progression of cardiovascular disease.61 Tele-
medicine has been used to prescribe and monitor dialysis in
the United States and other developed countries, though its
role in providing nephrologist oversight to dialysis units
managed by non-nephrologists in remote areas in LMICs
deserves further evaluation.62,63DEVELOPING AND IMPLEMENTING RESOURCE SENSITIVE
GUIDELINES
KDIGO is committed to ensuring the utility of its clinical
practice recommendations that have been developed based on
the best evidence. High-quality clinical trials, outcome
studies, and registries are nonexistent in LMICs presently,
with little hope of obtaining local data to inform and adapt
guideline recommendations to local context.64,65Kidney International (2016) 90, 1164–1174
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Figure 5 | Key players in the implementation of KDIGO guidelines in LMICs. LMIC, low- and middle-income countries.
V Jha et al.: Kidney care in low- and middle-income countries mee t ing repor tWhile all guideline-rating recommendations should be
considered when using available clinical practice guidelines, it
is suggested that grade 1 recommendations should be prior-
itized for adaptation because they are usually based on the
highest quality of evidence. Adaptation should be under the
jurisdiction of the local renal societies.
Country-based dissemination of the adapted guideline
version is best achieved through local publications, partici-
pation in local conferences/symposia or workshops. Case
presentations that illustrate how the guidelines are used to
optimize care are particularly well-received. Such collections
can be used as teaching tools for a recommended course of
action. “Train the trainers” could be an important focus of
such an initiative and as an implementation tool. A “bank”
consisting of easily understood algorithms to guide manage-
ment of patients under speciﬁc circumstances could be kept
for presentations at congresses and symposia. Continuing
medical education credits could increase the participation of
young doctors and thereby ensure wider dissemination of
guidelines. Special sessions at local congresses or webinars are
other methods of dissemination that could help caregivers
better understand the KDIGO process of guideline develop-
ment and implementation.Kidney International (2016) 90, 1164–1174Novel methods for guideline implementation include
public–private partnerships. Local pharmaceutical companies
can assist guideline dissemination as part of “detailing”.
Where possible, guideline recommendations should be
harmonized with those produced by other organizations with
overlapping interests (e.g., diabetology, hypertension, infec-
tious diseases, and public health etc.). Avoiding discordance is
essential to minimize confusion, assist uptake and facilitate
the educational process on KD to local caregivers.
Any adaptation must carry a reference to the original
guideline source. The diverse nature of diseases and health
systems in different LMICs may require different imple-
mentation approaches. However, a certain degree of unifor-
mity in adaptation is desirable, such as the requirement for an
auditing system.
A uniform and well-recognized simple adaptation formula
is the ADAPTE framework (Supplemental Figure S3).66
However, if other validated methods exist in a particular
country, these should be used for the adaptation and audit.
The style and language of the KDIGO guideline recom-
mendations is standardized and based on a Grading of Rec-
ommendations Assessment, Development and Evaluation
(GRADE) approach. Locally adapted versions should be user1171
meet ing repor t V Jha et al.: Kidney care in low- and middle-income countriesfriendly and rendered practical for application in local geog-
raphies. Allied health professionals must also be taken into
account in the translation and adaptation to ensure a wider
distribution and greater acceptance of the guidelines.
Comparisons of KDIGO guidelines with locally adapted
guidelines would serve to educate and improve the adaptation
process and is an ideal that all adapted guidelines should
aspire to. Online training from KDIGO with input and advice
from local caregivers can help this process, especially if vari-
ance exists between KDIGO recommendations and local
practice.
A suggested guideline adaptation and implementation
process for LMICs is shown in Figure 4.
Simplify communication and engage other professional
societies
The most commonly used guidelines need to penetrate pri-
mary care and cross-cutting specialties such as endocrinology
and cardiology, as these providers are more likely to
encounter individuals in earlier stages of CKD. Joint meetings
can help promote the provision of scalable and affordable
models of guideline-based care in their areas of inﬂuence.
This approach requires identiﬁcation of local champions who
can work with local societies. The messaging should be
developed such that the other specialists feel empowered
rather than threatened, especially while discussing referrals.
Adaptation should take into account both global science and
local resources.
CONCLUSION
The rising burden of NCDs has been recognized as a threat to
the global community that calls for urgent steps, as articu-
lated in the SDG 3.8. Because KDs are important contributors
to this burden, there is a critical requirement for the devel-
opment of an implementation framework tailored to the local
needs of health systems and to optimize the quality of care for
patients at risk for developing KD in limited-resource settings.
All health system stakeholders should be engaged in the
development and implementation of guideline-based care,
using a framework consistent with local policies. A multi-
pronged approach is required to align the kidney care delivery
model to the health care system. This includes leveraging
existing frameworks for care of communicable diseases and
NCDs and customizing them for the challenges of AKI and
CKD. Existing policies, payment systems, and care delivery
models should be utilized. The health care work force should
be empowered with technology to develop affordable, scal-
able, and acceptable models of care delivery. Support from
national, regional, and global professional societies is needed
for training and continuing professional development of ne-
phrologists, physicians, and NPHWs in implementation sci-
ence and understanding of health systems; developing
capacity to adapt guidelines; and integration of these princi-
ples in medical, paramedical, and nursing school curricula.
Figure 5 shows a suggested scheme of implementation for
guideline-based care in LMICs.1172Major gaps remain in the development and implementa-
tion of a “health systems” approach to overcome the barriers
and facilitate delivery of optimal guideline-based care for
patients with and at risk of developing KD. A robust inter-
national and culturally sensitive research agenda in this area is
essential. It is anticipated that this conference and future
planned work will provide the impetus to develop, evaluate,
and implement care frameworks in limited-resource settings.
The participants recognized the uniquely inﬂuential posi-
tion of KDIGO as an international collaboration in designing,
implementing, and testing effective and efﬁcient models of
guideline implementation to reduce KD burden, in collabo-
ration with like-minded organizations such as the Interna-
tional Society of Nephrology, national and regional nephrology
and physician societies, kidney foundations, and multilateral
organizations such as the World Health Organization.DISCLOSURE
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Figure S1. Age-speciﬁc prevalence estimates and absolute numbers
of men and women with chronic kidney disease worldwide. (A)
Stages 1–5. (B) Stages 3–5. Reproduced with permission from Mills KT,
Xu Y, Zhang W, et al. A systematic analysis of worldwide population-
based data on the global burden of chronic kidney disease in 2010.
Kidney Int. 2015;88:950–957.10
Figure S2. Global prevalence of end-stage kidney disease for 2012
with estimated numbers of patients receiving and requiring renal
replacement therapy by region. Reproduced with permission from
Romanowski K, Clark EG, Levin A, et al. Tuberculosis and chronic
kidney disease: an emerging global syndemic. Kidney Int. 2016;90:
34–40.67
Figure S3. Overview of the ADAPTE process. Reproduced with
permission from The ADAPTE Collaboration (2009). The ADAPTEKidney International (2016) 90, 1164–1174
V Jha et al.: Kidney care in low- and middle-income countries mee t ing repor tProcess: Resource Toolkit for Guideline Adaptation. Version 2.0.
Available at: http://www.g-i-n.net.66
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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